Praetorian Bio is developing a first-in-class vaccine targeting the microbial drivers of dental cavities at their root. The approach aims to generate broad mucosal immune responses that provide durable protection against complex, biofilm-associated pathogens including Streptococcus mutans. A schematic overview of the mechanism is provided below.
BALB/c mice were intranasally immunized on Days 0 and 21 with different vaccine formulations. All included a potent mucosal adjuvant, except Concept B, which was also tested without adjuvant. Two weeks post-boost, serum and nasal washes were collected and reactivity against whole-cell Streptococcus mutans was quantified by ELISA.
All vaccine candidates induced strong systemic IgG and IgA responses. The absence of adjuvant markedly reduced antibody titers, confirming the adjuvant effect. Most importantly, all candidates also elicited S. mutans–specific mucosal IgA in nasal washes.
We target Streptococcus mutans and Porphyromonas gingivalis with highly specific antigens — delivering protective immune responses without disrupting the beneficial oral microbiome.
Our vaccines stop pathogens at their point of entry — the mouth — preventing cavities, gum disease, and their systemic consequences before they take hold.
From design to manufacturing, our pipeline is built with scalability, manufacturability, and regulatory alignment in mind, ensuring global accessibility.